{
    "eid": "2-s2.0-84924322803",
    "title": "Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis",
    "cover-date": "2015-02-01",
    "subject-areas": [
        {
            "$": "Dermatology",
            "@code": "2708"
        }
    ],
    "keywords": [
        "Cardiovascular disease risk",
        "Disease characteristics",
        "Efficacy",
        "Etanercept"
    ],
    "authors": [
        "Luis Puig"
    ],
    "citedby-count": 29,
    "ref-count": 54,
    "ref-list": [
        "About Psoriasis: Statistics",
        "The concept of psoriasis as a systemic inflammation: Implications for disease management",
        "Psoriatic arthritis from Wright's Era until today",
        "Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality",
        "The risk of mortality in patients with psoriasis: Results from a population-based study",
        "Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the general practice research database",
        "Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis",
        "Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis.",
        "Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis",
        "The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation Patient-Membership Survey",
        "Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health",
        "Work disability in psoriatic arthritis: A systematic review",
        "Psoriatic arthritis: Epidemiology, clinical features, course, and outcome",
        "Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial",
        "Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial",
        "The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)",
        "J Dermatol Treat",
        "Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: Results from the PRISTINE trial",
        "Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity",
        "Standards of medical care in diabetes-2010",
        "Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)",
        "Hard Coronary Heart Disease (10-Year Risk)",
        "Prediction of coronary heart disease using risk factor categories",
        "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.",
        "Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score",
        "UK Population Norms for EQ-5D (Measurement and Valuation of Health National Survey)",
        "Health-related quality of life measured with EQ-5D in patients treated for depression in primary care",
        "Measuring disability and quality of life in established rheumatoid arthritis",
        "Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease",
        "Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States",
        "Health-related quality of life is related to COPD disease severity",
        "Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial",
        "EuroQol - a new facility for the measurement of health-related quality of life",
        "Quality of Life and Pharmacoeconomics in Clinical Trials",
        "Modeling Valuations for EuroQol Health States",
        "The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: Properties, applications, and interpretation",
        "Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales",
        "Fatigue in cancer patients compared with fatigue in the general United States population",
        "Psychometric properties of the Medical Outcomes Study Sleep measure",
        "Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain",
        "The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument",
        "Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions",
        "Psoriasis and cardiovascular risk: Strength in numbers",
        "Psoriasis and the risk of diabetes and hypertension: A prospective study of us female nurses",
        "Psoriasis and metabolic disease: Epidemiology and pathophysiology",
        "Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review",
        "Comorbidities of psoriatic arthritis - Metabolic syndrome and prevention: A report from the GRAPPA 2010 annual meeting",
        "Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey",
        "Differences in body mass index among individuals with PsA, psoriasis, RA and the general population",
        "Psoriasis and vascular disease-risk factors and outcomes: A systematic review of the literature",
        "Metabolic Syndrome and Risk of Acute Myocardial Infarction. A Case-Control Study of 26,903 Subjects From 52 Countries",
        "HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms",
        "Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis",
        "Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: A Danish real-world cohort study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Taipei",
            "affilname": "National Taiwan University Hospital",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Cerdanyola del Valles",
            "affilname": "Universitat Aut\u00f2noma de Barcelona",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Cleveland",
            "affilname": "Cleveland Clinic Foundation",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "New York",
            "affilname": "Pfizer Inc.",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Feldkirch",
            "affilname": "Academic Teaching Hospital Feldkirch",
            "affiliation-country": "Austria"
        }
    ],
    "funding": []
}